2052591-32-7
2052591-32-7
Chemical Structure
Samrotamab
Synonym(s): PR-1498487
- CAS No.: 2052591-32-7
- Formula:N/A
- Molecular Weight:(145.92 kDa)
IUPAC Name: 6-(4-aminopiperidin-1-yl)nicotinic acid hydrochloride
SMILES: [Samrotamab]
Biological Activity: Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Samrotamab | 96.00% | Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dong SW, et al. The role of LRRC15-SCG5 in ECM protein binding as a prognostic signature for urothelial carcinoma. Am J Cancer Res. 2025 May 25;15(5):2301-2318.
- [2]. Demetri GD, et al. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res. 2021 Jul 1;27(13):3556-3566. [Content Brief]
Keywords
